Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because the company did not ...